Interleukin 2 (IL 2) administered in vivo: influence of IL 2 route and timing on T cell growth - PubMed (original) (raw)
Comparative Study
. 1985 Jun;134(6):3895-900.
- PMID: 3872906
Comparative Study
Interleukin 2 (IL 2) administered in vivo: influence of IL 2 route and timing on T cell growth
M A Cheever et al. J Immunol. 1985 Jun.
Abstract
The influence of the route and the frequency of IL 2 administration on the ability of IL 2 to induce the growth of activated T cells in vivo was evaluated. Initial pharmacokinetic studies confirmed that i.v. injection of IL 2 results in a relatively high peak serum concentration, but a short serum half-life. By contrast, i.p. or subcutaneous (s.c.) injection of IL 2 results in a lower peak concentration but a prolonged serum half-life. The bioavailability of IL 2 administered by these routes was assessed by measuring the in vivo growth of adoptively transferred T cells that had been previously cultured long-term with IL 2, because the growth of such cells in vivo has been shown to be proportional to the dose of IL 2 administered. The results demonstrated that i.p., s.c., or i.v. administration of IL 2 each resulted in marked donor T cell growth in vivo. Thus, IL 2 can function in vivo at sites distant to the sites of injection. In addition, the magnitude of T cell growth in vivo varied dependent on the route of IL 2 administration and correlated with the length of time IL 2 was detectable in serum, rather than the peak level achieved (i.e., IL 2 inoculated i.v. had the highest peak concentration but was least effective). As suggested by these findings, dividing the total dose of IL 2 into frequent low-dose injections was more effective in inducing T cell growth in vivo than was dividing the total dose of IL 2 into less frequent higher-dose injections. These studies confirm the great potential for IL 2 to induce the growth of activated of T cells in vivo and demonstrate that the rate of T cell growth reflects not only the dose but also the route and timing of IL 2 administration.
Similar articles
- Interleukin 2 administered in vivo induces the growth of cultured T cells in vivo.
Cheever MA, Greenberg PD, Irle C, Thompson JA, Urdal DL, Mochizuki DY, Henney CS, Gillis S. Cheever MA, et al. J Immunol. 1984 May;132(5):2259-65. J Immunol. 1984. PMID: 6609193 - Interleukin-2 administered in vivo induces the growth and augments the function of cultured T cells in vivo.
Cheever MA, Thompson JA, Kern DE, Greenberg PD. Cheever MA, et al. J Biol Response Mod. 1984 Oct;3(5):462-7. J Biol Response Mod. 1984. PMID: 6334133 - [Novel vaccines against M. tuberculosis].
Okada M. Okada M. Kekkaku. 2006 Dec;81(12):745-51. Kekkaku. 2006. PMID: 17240920 Review. Japanese. - Effects of route and formulation on clinical pharmacokinetics of interleukin-2.
Anderson PM, Sorenson MA. Anderson PM, et al. Clin Pharmacokinet. 1994 Jul;27(1):19-31. doi: 10.2165/00003088-199427010-00003. Clin Pharmacokinet. 1994. PMID: 7955769 Review.
Cited by
- NKTR-358: A novel regulatory T-cell stimulator that selectively stimulates expansion and suppressive function of regulatory T cells for the treatment of autoimmune and inflammatory diseases.
Dixit N, Fanton C, Langowski JL, Kirksey Y, Kirk P, Chang T, Cetz J, Dixit V, Kim G, Kuo P, Maiti M, Tang Y, VanderVeen LA, Zhang P, Lee M, Ritz J, Kamihara Y, Ji C, Rubas W, Sweeney TD, Doberstein SK, Zalevsky J. Dixit N, et al. J Transl Autoimmun. 2021 May 6;4:100103. doi: 10.1016/j.jtauto.2021.100103. eCollection 2021. J Transl Autoimmun. 2021. PMID: 34041473 Free PMC article. - Weekly injection of IL-2 using an injectable hydrogel reduces autoimmune diabetes incidence in NOD mice.
Nagy N, Kaber G, Kratochvil MJ, Kuipers HF, Ruppert SM, Yadava K, Yang J, Heilshorn SC, Long SA, Pugliese A, Bollyky PL. Nagy N, et al. Diabetologia. 2021 Jan;64(1):152-158. doi: 10.1007/s00125-020-05314-1. Epub 2020 Oct 30. Diabetologia. 2021. PMID: 33125521 Free PMC article. - Intravenous ascorbic acid as an adjuvant to interleukin-2 immunotherapy.
Wagner SC, Markosian B, Ajili N, Dolan BR, Kim AJ, Alexandrescu DT, Dasanu CA, Minev B, Koropatnick J, Marincola FM, Riordan NH. Wagner SC, et al. J Transl Med. 2014 May 13;12:127. doi: 10.1186/1479-5876-12-127. J Transl Med. 2014. PMID: 24884532 Free PMC article. Review. - Inflammation programs self-reactive CD8+ T cells to acquire T-box-mediated effector function but does not prevent deletional tolerance.
Jackson SR, Yuan J, Berrien-Elliott MM, Chen CL, Meyer JM, Donlin MJ, Teague RM. Jackson SR, et al. J Leukoc Biol. 2014 Sep;96(3):397-410. doi: 10.1189/jlb.1A0913-500RR. Epub 2014 May 13. J Leukoc Biol. 2014. PMID: 24823810 Free PMC article. - The in vivo expansion rate of properly stimulated transferred CD8+ T cells exceeds that of an aggressively growing mouse tumor.
Hwang LN, Yu Z, Palmer DC, Restifo NP. Hwang LN, et al. Cancer Res. 2006 Jan 15;66(2):1132-8. doi: 10.1158/0008-5472.CAN-05-1679. Cancer Res. 2006. PMID: 16424050 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Research Materials